Insulet Reports First Quarter 2026 Financial Results
Insulet Corporation announced its financial results for the first quarter of 2026, reporting a revenue of $761.7 million, which represents a 33.9% increase compared to the previous year. The total revenue from its Omnipod products was $758.4 million, exceeding the company’s previous guidance range of 25%-27% growth at constant currency rates.
ACTON, Mass.–(BUSINESS WIRE)–Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its financial results for the three months ended March 31, 2026. First Quarter Financial Highlights: Revenue of $761.7 million, up 33.9%, or 30.1% in constant currency1, and exceeded the high end of the Company’s guidance range of 25% – 27% at constant currency rates Total Omnipod revenue of $758.4